智通财经APP获悉，摩根士丹利近日发布研报，针对减肥药领域近期动态发表点评。信诺(CI.US)旗下Evernorth最近宣布了一项新的福利方案，将患者每月使用礼来(LLY.US)Zepbound和诺和诺德(NVO.US)Wegovy的自付费用上限设定 ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

对于礼来公司的Zepbound，标价大约是每月1100美元，而净价是725美元。 Evernorth和CVS Caremark的这些新安排可能会使雇主支付的净价格更低，就像美国政府 ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Cigna’s Evernorth has reached new deals with manufacturers Eli Lilly and Novo Nordisk to cap patients’ copays for pricey GLP-1 weight loss medications, the health services business announced Wednesday ...

礼来公司(LLY.US)于上周日宣布，根据一项头对头对比试验的数据，其减肥药物Zepbound在减少腰围等五项减肥指标上优于诺和诺德公司(NVO.US)的Wegovy。

财联社5月12日讯（编辑 牛占林）当地时间周日(5月11日)，礼来公布的对比试验数据显示，其减肥药物Zepbound的减重效果，要比竞争对手诺和诺德的 ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200.

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Evernorth said in an announcement that through its Express Scripts arm it negotiated directly with the manufacturers for Wegovy and Zepbound—Novo Nordisk and Eli Lilly, respectively—to cap ...

The benefit could nudge more Evernorth clients to cover GLP-1s. Currently, only half of its employer clients cover drugs like Wegovy and Zepbound for weight management, executives said on a call ...

The company's Evernorth Health Services subsidiary has launched a pharmacy benefit offering that caps monthly copayments for Wegovy and Zepbound, two blockbuster glucagon-like peptide-1 agonists ...